Howard W. Robin, President and CEO of Nektar Therapeutics, filed a Form 4 on November 19, 2026, disclosing the sale of 429 shares of common stock on November 17, 2026, to cover tax withholding obligations tied to RSU vesting.

Key Highlights

  • Transaction date: 429 shares of Nektar Therapeutics common stock were disposed of on November 17, 2026, with transaction code "S."
  • Purpose of sale: According to the filing, the shares were sold "to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person."
  • Weighted average price: The reported sale price was $35.85 per share, executed across multiple trades at prices ranging from $35.57 to $36.31.
  • Remaining direct holdings: Following the transaction, Robin directly beneficially owned 54,198 shares of common stock.
  • Indirect holdings: An additional 28 shares are held indirectly by Robin's spouse.
  • Roles: Robin is identified in the filing as both a Director and Officer (President and CEO) of Nektar Therapeutics (NASDAQ:NKTR).

RSU Vesting Triggers Tax-Related Share Disposal by Nektar Therapeutics President and CEO

Howard W. Robin, who serves as President, CEO, and Director of Nektar Therapeutics, disclosed a sale of 429 shares of the company's common stock on November 17, 2026. The filing, signed by Elizabeth Zhang as Attorney-in-Fact and submitted on November 19, 2026, identifies the transaction code as "S" and classifies the disposal as a direct holding.

According to the filing, the sale was not discretionary. The shares were disposed of solely to satisfy tax withholding requirements connected to the vesting of restricted stock units (RSUs) held by Robin. The weighted average sale price was reported as $35.85 per share, though the filing notes the transaction was executed across multiple trades at prices ranging from $35.57 to $36.31. The filing states that Robin "undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer."

After the disposal, Robin's direct beneficial ownership stands at 54,198 shares of Nektar Therapeutics common stock. An additional 28 shares are reported as indirectly owned through Robin's spouse. No derivative securities transactions were reported in this filing.

What Was Disclosed

The filing reports a tax withholding-related sale of 429 Nektar Therapeutics shares by President and CEO Howard W. Robin on November 17, 2026, at a weighted average price of $35.85, leaving him with direct ownership of 54,198 shares.